Literature DB >> 25644940

A clinicopathological cohort study of liver pathology in 301 patients with human immunodeficiency virus/acquired immune deficiency syndrome.

Mark W Sonderup1, Helen Wainwright, Pauline Hall, Henry Hairwadzi, C Wendy N Spearman.   

Abstract

UNLABELLED: Liver disease complicates human immunodeficiency virus (HIV)/acquired immune deficiency syndrome; however, liver pathology data are limited, particularly from high HIV prevalence countries. We investigated the spectrum and clinicopathological correlates of liver pathology in a high HIV burden setting. In a single-center study, all HIV/acquired immune deficiency syndrome patients with complete clinical and demographic data who underwent liver biopsy were analyzed and clinicopathologically assessed by hepatologists and one of two experienced liver pathologists. We evaluated 301 patients, with a median age of 34 (interquartile range 29-40) years. Women (n = 143) were younger than men (n = 158), with a median age of 33 (interquartile range 28-37) versus 35 (interquartile range 31-41) years, P = 0.001. The majority, 76.1%, were black African. Median CD4 at time of biopsy was 127 (52-260) cells/mm(3) . Drug-induced liver injury was the predominant finding (42.2%), followed by granulomatous inflammation (29%), steatosis/steatohepatitis (19.3%), hepatitis B (19%), and hepatitis C coinfection (3.3%), with more than one pathology in 16.2%. With granulomatous inflammation, 52% met the criteria for tuberculosis immune reconstitution syndrome. By univariate analysis, cotrimoxazole and antiretroviral therapy conferred risk for drug injury (odds ratio [OR] = 2.78 [1.72-4.48], P < 0.001; OR = 1.69 [1.06-2.68], P = 0.027). In multivariate analysis, cotrimoxazole was associated with a cholestatic or ductopenic injury (OR = 7.05 [2.50-19.89], P < 0.001; OR = 17.6 [3.26-95.3], P < 0.0001); efavirenz was associated with nonspecific hepatitis or submassive necrosis (OR = 4.3 [1.92-9.83], P < 0.001; OR = 10.46 [2.7-40.5], P < 0.001). Cholestatic injury was associated with female gender and a CD4 of >200 cells/mm(3) , and submassive necrosis was associated with younger age. Hepatitis B demonstrated no association.
CONCLUSION: In a high HIV burden area, drug-induced liver injury due to antiretroviral therapy and cotrimoxazole was a frequent clinicopathological finding; Mycobacterium tuberculosis was the leading opportunistic infection, with more than half of patients fulfilling criteria for tuberculosis immune reconstitution syndrome; liver biopsy remains a useful diagnostic procedure in this setting.
© 2015 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25644940     DOI: 10.1002/hep.27710

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  10 in total

1.  Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Co-infected with Human Immunodeficiency Virus (HIV): Results of the HBV-HIV Cohort Study.

Authors:  Richard K Sterling; Abdus S Wahed; Wendy C King; David E Kleiner; Mandana Khalili; Mark Sulkowski; Raymond T Chung; Mamta K Jain; Mauricio Lisker-Melman; David K Wong; Marc G Ghany
Journal:  Am J Gastroenterol       Date:  2019-05       Impact factor: 10.864

2.  Alcohol use, viral hepatitis and liver fibrosis among HIV-positive persons in West Africa: a cross-sectional study.

Authors:  Antoine Jaquet; Gilles Wandeler; Marcellin Nouaman; Didier K Ekouevi; Judicaël Tine; Akouda Patassi; Patrick A Coffie; Aristophane Tanon; Moussa Seydi; Alain Attia; François Dabis
Journal:  J Int AIDS Soc       Date:  2017-02-17       Impact factor: 5.396

3.  Hepatic tuberculosis in human immunodeficiency virus co-infected adults: a case series of South African adults.

Authors:  Lilishia Gounder; Pravikrishnen Moodley; Paul K Drain; Andrew J Hickey; Mahomed-Yunus S Moosa
Journal:  BMC Infect Dis       Date:  2017-02-01       Impact factor: 3.090

4.  Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis.

Authors:  Raphael Mohr; Christoph Boesecke; Leona Dold; Robert Schierwagen; Carolynne Schwarze-Zander; Jan-Christian Wasmuth; Insa Weisensee; Jürgen Kurt Rockstroh; Jonel Trebicka
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

Review 5.  Mechanistic insights into antiretroviral drug-induced liver injury.

Authors:  Jamie N Pillaye; Mohlopheni J Marakalala; Nonhlanhla Khumalo; Wendy Spearman; Hlumani Ndlovu
Journal:  Pharmacol Res Perspect       Date:  2020-08

6.  Prevalence and Risk Factors for Hepatic Steatosis in Children With Perinatal HIV on Early Antiretroviral Therapy Compared to HIV-Exposed Uninfected and HIV-Unexposed Children.

Authors:  Penelope C Rose; Etienne D Nel; Mark F Cotton; Richard D Pitcher; Kennedy Otwombe; Sara H Browne; Steve Innes
Journal:  Front Pediatr       Date:  2022-06-09       Impact factor: 3.569

7.  Adiponectin and the steatosis marker Chi3L1 decrease following switch to raltegravir compared to continued PI/NNRTI-based antiretroviral therapy.

Authors:  Obiageli Offor; Netanya Utay; David Reynoso; Anoma Somasunderam; Judith Currier; Jordan Lake
Journal:  PLoS One       Date:  2018-05-10       Impact factor: 3.240

8.  Effectiveness of a psychological intervention delivered by general nurses for alcohol use disorders in people living with HIV in Zimbabwe: a cluster randomized controlled trial.

Authors:  Munyaradzi Madhombiro; Martin Kidd; Bazondlile Dube; Michelle Dube; Wilson Mutsvuke; Thabani Muronzie; Danai Tavonga Zhou; Sarah Derveeuw; Dixon Chibanda; Alfred Chingono; Simbarashe Rusakaniko; Alan Hutson; Gene D Morse; Melanie A Abas; Soraya Seedat
Journal:  J Int AIDS Soc       Date:  2020-12       Impact factor: 6.707

9.  Macrophages Modulate Hepatic Injury Involving NLRP3 Inflammasome: The Example of Efavirenz.

Authors:  Fernando Alegre; Alberto Martí-Rodrigo; Miriam Polo; Dolores Ortiz-Masiá; Celia Bañuls; Marcello Pinti; Ángeles Álvarez; Nadezda Apostolova; Juan V Esplugues; Ana Blas-García
Journal:  Biomedicines       Date:  2022-01-05

10.  The Correlated Risk Factors for Severe Liver Damage Among HIV-Positive Inpatients With Abnormal Liver Tests.

Authors:  Sheng Liu; Ying Zhou; Yu Wang; Cheng Bo Li; Wen Wang; Xu Lu; Pei Liu; Qing Hai Hu; Ying Wen
Journal:  Front Med (Lausanne)       Date:  2022-02-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.